Vincent Cabaud Gibouin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vincent Cabaud Gibouin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Gaëtan Jego
INSERM, LNC UMR1231, team HSP-Pathies, University of Bourgogne Franche-Comté, F-21000 Dijon, France
4 shared publications - Manon Durand
INSERM, UMR1231, Université de Bourgogne, Dijon, France
3 shared publications Carmen Garrido
INSERM, UMR1231, Université de Bourgogne, Dijon, France
2 shared publications- Antoine Taly
Université Paris-Cite et CNRS
1 shared publication Brigitte Sola
INSERM, U1245, Normandy University, Caen, France
1 shared publication- Brigitte Sola
Normandie University, INSERM, University of Caen, 14118 Caen, France
1 shared publication
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation fonctionnelle des premiers inhibiteurs d’HSP110
Les protéines de choc thermique sont des chaperons moléculaires fortement exprimés dans les hémopathies malignes. Mon laboratoire de thèse a montré que la protéine de choc thermique HSP110 est une nouvelle cible thérapeutique de première importance dans le cancer colorectal et dans les lymphomes non-Hodgkiniens. Une stratégie de criblage d’une chimiothèque a permis l’identification de deux molécules capables d’inhiber spécifiquement l’activité chaperonne de HSP110. Mon objectif de thèse a été de caractériser et de valider fonctionnellement ces molécules nouvellement identifiées dans les lymphomes B diffus à grandes cellules. J’ai montré qu’une de ces molécules limite l’interaction de HSP110 avec la protéine de signalisation SYK, kinase essentielle de la voie de signalisation du BCR. Cet inhibiteur réduit la croissance des cellules de lymphomes in vitro et in vivo. Elle réduit aussi l’activation de la voie NF-κB, voie essentielle de survie. J’ai enfin montré que l’inhibition de cette voie par notre inhibiteur, en combinaison avec des inhibiteurs de la voie PI3K, bloque complètement la croissance tumorale in vivo.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation fonctionnelle des premiers inhibiteurs d’HSP110
Les protéines de choc thermique sont des chaperons moléculaires fortement exprimés dans les hémopathies malignes. Mon laboratoire de thèse a montré que la protéine de choc thermique HSP110 est une nouvelle cible thérapeutique de première importance dans le cancer colorectal et dans les lymphomes non-Hodgkiniens. Une stratégie de criblage d’une chimiothèque a permis l’identification de deux molécules capables d’inhiber spécifiquement l’activité chaperonne de HSP110. Mon objectif de thèse a été de caractériser et de valider fonctionnellement ces molécules nouvellement identifiées dans les lymphomes B diffus à grandes cellules. J’ai montré qu’une de ces molécules limite l’interaction de HSP110 avec la protéine de signalisation SYK, kinase essentielle de la voie de signalisation du BCR. Cet inhibiteur réduit la croissance des cellules de lymphomes in vitro et in vivo. Elle réduit aussi l’activation de la voie NF-κB, voie essentielle de survie. J’ai enfin montré que l’inhibition de cette voie par notre inhibiteur, en combinaison avec des inhibiteurs de la voie PI3K, bloque complètement la croissance tumorale in vivo.
- 21 June 2024
- Published by Springer Nature in Leukemia
First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is driven by aberrant activation of the B-cell receptor (BCR) and the TLR/MyD88 signaling pathways. The heat-shock protein HSP110 is a candidate for their regulation as it stabilizes MyD88. However, its role in overall BCR signaling remains unknown. Here, we used first-in-class HSP110 inhibitors to address this question. HSP110 inhibitors decreased the survival of several ABC-DLBCL cell lines in vitro and in vivo, and reduced the phosphorylation of BCR signaling kinases, including BTK and SYK. We identified an interaction between HSP110 and SYK and demonstrated that HSP110 promotes SYK phosphorylation. Finally, the combination of the HSP110 inhibitor with the PI3K inhibitor copanlisib decreases SYK/BTK and AKT phosphorylation synergistically, leading to suppression of tumor growth in cell line xenografts and strong reduction in patient-derived xenografts. In conclusion, by regulating the BCR/TLR signaling pathway, HSP110 inhibitors are potential drug candidates for ABC-DLBCL patients.
- 21 June 2024
- Published by Springer Nature in Leukemia
First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is driven by aberrant activation of the B-cell receptor (BCR) and the TLR/MyD88 signaling pathways. The heat-shock protein HSP110 is a candidate for their regulation as it stabilizes MyD88. However, its role in overall BCR signaling remains unknown. Here, we used first-in-class HSP110 inhibitors to address this question. HSP110 inhibitors decreased the survival of several ABC-DLBCL cell lines in vitro and in vivo, and reduced the phosphorylation of BCR signaling kinases, including BTK and SYK. We identified an interaction between HSP110 and SYK and demonstrated that HSP110 promotes SYK phosphorylation. Finally, the combination of the HSP110 inhibitor with the PI3K inhibitor copanlisib decreases SYK/BTK and AKT phosphorylation synergistically, leading to suppression of tumor growth in cell line xenografts and strong reduction in patient-derived xenografts. In conclusion, by regulating the BCR/TLR signaling pathway, HSP110 inhibitors are potential drug candidates for ABC-DLBCL patients.
- Open Access
- 22 May 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
Background: Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor development due to multiple recurrent mutations, particularly in STAT6. Furthermore, the XPO1 gene that encodes exportin 1 (XPO1) shows a frequent point mutation (E571K) resulting in an altered export of hundreds of cargo proteins, which may impact the success of future therapies in PMBL and cHL. Therefore, targeted therapies have been envisioned for these signaling pathways and mutations. Methods: To identify novel molecular targets that could overcome the treatment resistance that occurs in PMBL and cHL patients, we have explored the efficacy of a first-in-class HSP110 inhibitor (iHSP110-33) alone and in combination with selinexor, a XPO1 specific inhibitor, both in vitro and in vivo. Results: We show that iHSP110-33 decreased the survival of several PMBL and cHL cell lines and the size of tumor xenografts. We demonstrate that HSP110 is a cargo of XPO1wt as well as of XPO1E571K. Using immunoprecipitation, proximity ligation, thermophoresis and kinase assays, we showed that HSP110 directly interacts with STAT6 and favors its phosphorylation. The combination of iHSP110-33 and selinexor induces a synergistic reduction of STAT6 phosphorylation and of lymphoma cell growth in vitro and in vivo. In biopsies from PMBL patients, we show a correlation between HSP110 and STAT6 phosphorylation levels. Conclusions: These findings suggest that HSP110 could be proposed as a novel target in PMBL and cHL therapy.
- 22 May 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
Open AccessA first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
Background: Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor development due to multiple recurrent mutations, particularly in STAT6. Furthermore, the XPO1 gene that encodes exportin 1 (XPO1) shows a frequent point mutation (E571K) resulting in an altered export of hundreds of cargo proteins, which may impact the success of future therapies in PMBL and cHL. Therefore, targeted therapies have been envisioned for these signaling pathways and mutations. Methods: To identify novel molecular targets that could overcome the treatment resistance that occurs in PMBL and cHL patients, we have explored the efficacy of a first-in-class HSP110 inhibitor (iHSP110-33) alone and in combination with selinexor, a XPO1 specific inhibitor, both in vitro and in vivo. Results: We show that iHSP110-33 decreased the survival of several PMBL and cHL cell lines and the size of tumor xenografts. We demonstrate that HSP110 is a cargo of XPO1wt as well as of XPO1E571K. Using immunoprecipitation, proximity ligation, thermophoresis and kinase assays, we showed that HSP110 directly interacts with STAT6 and favors its phosphorylation. The combination of iHSP110-33 and selinexor induces a synergistic reduction of STAT6 phosphorylation and of lymphoma cell growth in vitro and in vivo. In biopsies from PMBL patients, we show a correlation between HSP110 and STAT6 phosphorylation levels. Conclusions: These findings suggest that HSP110 could be proposed as a novel target in PMBL and cHL therapy.
- Open Access
Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches
Heat-shock proteins (HSPs) are powerful chaperones that provide support for cellular functions under stress conditions but also for the homeostasis of basic cellular machinery. All cancer cells strongly rely on HSPs, as they must continuously adapt to internal but also microenvironmental stresses to survive. In solid tumors, HSPs have been described as helping to correct the folding of misfolded proteins, sustain oncogenic pathways, and prevent apoptosis. Leukemias and lymphomas also overexpress HSPs, which are frequently associated with resistance to therapy. HSPs have therefore been proposed as new therapeutic targets. Given the specific biology of hematological malignancies, it is essential to revise their role in this field, providing a more adaptable and comprehensive picture that would help design future clinical trials. To that end, this review will describe the different pathways and functions regulated by HSP27, HSP70, HSP90, and, not least, HSP110 in leukemias and lymphomas.
Open AccessHeat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches
Heat-shock proteins (HSPs) are powerful chaperones that provide support for cellular functions under stress conditions but also for the homeostasis of basic cellular machinery. All cancer cells strongly rely on HSPs, as they must continuously adapt to internal but also microenvironmental stresses to survive. In solid tumors, HSPs have been described as helping to correct the folding of misfolded proteins, sustain oncogenic pathways, and prevent apoptosis. Leukemias and lymphomas also overexpress HSPs, which are frequently associated with resistance to therapy. HSPs have therefore been proposed as new therapeutic targets. Given the specific biology of hematological malignancies, it is essential to revise their role in this field, providing a more adaptable and comprehensive picture that would help design future clinical trials. To that end, this review will describe the different pathways and functions regulated by HSP27, HSP70, HSP90, and, not least, HSP110 in leukemias and lymphomas.
- Open Access
XPO1E571K Mutation Modifies Exportin 1 Localisation and Interactome in B-Cell Lymphoma
The XPO1 gene encodes exportin 1 (XPO1) that controls the nuclear export of cargo proteins and RNAs. Almost 25% of primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) cases harboured a recurrent XPO1 point mutation (NM_003400, chr2:g61718472C>T) resulting in the E571K substitution within the hydrophobic groove of the protein, the site of cargo binding. We investigated the impact of the XPO1E571K mutation using PMBL/cHL cells having various XPO1 statuses and CRISPR–Cas9-edited cells in which the E571K mutation was either introduced or knocked-out. We first confirmed that the mutation was present in both XPO1 mRNA and protein. We observed that the mutation did not modify the export capacity but rather the subcellular localisation of XPO1 itself. In particular, mutant XPO1 bound to importin β1 modified the nuclear export/import dynamics of relevant cargoes.
Open AccessXPO1E571K Mutation Modifies Exportin 1 Localisation and Interactome in B-Cell Lymphoma
The XPO1 gene encodes exportin 1 (XPO1) that controls the nuclear export of cargo proteins and RNAs. Almost 25% of primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) cases harboured a recurrent XPO1 point mutation (NM_003400, chr2:g61718472C>T) resulting in the E571K substitution within the hydrophobic groove of the protein, the site of cargo binding. We investigated the impact of the XPO1E571K mutation using PMBL/cHL cells having various XPO1 statuses and CRISPR–Cas9-edited cells in which the E571K mutation was either introduced or knocked-out. We first confirmed that the mutation was present in both XPO1 mRNA and protein. We observed that the mutation did not modify the export capacity but rather the subcellular localisation of XPO1 itself. In particular, mutant XPO1 bound to importin β1 modified the nuclear export/import dynamics of relevant cargoes.